{
    "Trade/Device Name(s)": [
        "Lumipulse G CA19-9-N",
        "Lumipulse G CA19-9-N Immunoreaction Cartridges"
    ],
    "Submitter Information": "Fujirebio Diagnostics, Inc.",
    "510(k) Number": "K191973",
    "Predicate Device Reference 510(k) Number(s)": [
        "K052000"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NIG"
    ],
    "Summary Letter Date": "October 22, 2019",
    "Summary Letter Received Date": "July 24, 2019",
    "Submission Date": "July 22, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "CA 19-9"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "SST (serum separator tube)",
        "Red top tube",
        "K2EDTA tube",
        "Sodium heparin tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "LUMIPULSE G System",
        "LUMIPULSE G1200 System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent Enzyme Immunoassay (CLEIA)"
    ],
    "Methodologies": [
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Immunoreaction Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for Fujirebio Diagnostics Lumipulse G CA19-9-N assay for quantitative CA 19-9 measurement in serum and plasma on the LUMIPULSE G System as an aid in the management of pancreatic cancer patients.",
    "Indications for Use Summary": "For serial measurement of CA 19-9 to aid in the management of patients diagnosed with exocrine pancreatic cancer with detectable CA 19-9, used in conjunction with other clinical methods.",
    "fda_folder": "Immunology"
}